DCDaniel James Clark

Daniel James Clark

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Daniel James Clark has a total of 37 co-authors. Here are the top co-authors by number of shared publications:

  • Adam P. Ostendorf

    Department of Pediatrics, Division of Neurology Nationwide Children's Hospital and The Ohio State University College of Medicine Columbus Ohio USA

    1 shared publication
  • Alexander Andrews

    1 shared publication
  • Andrea Debs

    From the Division of Pediatric Neurology (J.R.M., S.M.A., D.V.F.A., C.W.B., A.P.O., J.D.E.T., J.V., A.D.P.), Department of Pediatrics, Nationwide Children's Hospital, and The Ohio State University; The Center for Clinical Excellence (W.P., A.D.P.) ; Information Technology Research & Innovation (S.W.R.), and Division of Pediatric Neurology (J.C., D.J.C., A.D., D.D., M.K., J.H., M.C.T.), Department of Pediatrics, Nationwide Children's Hospital, Columbus, OH

    1 shared publication
  • Andy Witten

    1 shared publication
  • Angela Sarkisian

    1 shared publication
  • Anup D. Patel

    Department of Pediatrics, Division of Pediatric Neurology, Nationwide Children's Hospital, The Ohio State University, Columbus; and

    1 shared publication

Latest Publications

  • Admission Clinical and EEG Features Associated With Mortality and Long-term Neurologic and Cognitive Outcomes in Pediatric Cerebral Malaria

    by Daniel J. Clark, Caitlin Bond, Alexander Andrews, Daniel J. Muller, Angela Sarkisian, Robert O. Opoka, Richard Idro, Paul Bangirana, Andy Witten, Nicholas J. Sausen, et al.

    Background For children with cerebral malaria, mortality is high, and, in survivors, long-term neurologic and cognitive dysfunction are common. While specific clinical factors are associated with death or long-term neurocognitive morbidity in cerebral malaria, the association of EEG features with these outcomes, particularly neurocognitive outcomes, is less well characterized. Methods In this prospective cohort study of 149 children 6 months to 12 years of age who survived cerebral malaria in Kampala, Uganda, we evaluated whether depth of coma, number of clinical seizures, or EEG features during hospitalization were associated with mortality during hospitalization, short and long-term neurologic deficits, or long-term cognitive outcomes (overall cognition, attention, memory) over 2-year follow-up. Results Higher Blantyre or Glasgow coma scores (BCS and GCS, respectively), higher background voltage, and presence of normal reactivity on EEG were each associated with lower mortality. Among clinical and EEG features, the presence of >4 seizures on admission had the best combination of negative and positive predictive values for neurologic deficits in follow-up. In multivariable modeling of cognitive outcomes, number of seizures and specific EEG features showed independent association with better outcomes. In children <5 years throughout the study, seizure number and presence of vertex sharp waves were independently associated with better post-hospitalization cognitive performance; faster dominant frequency with better attention; and higher average background voltage and faster dominant background frequency with better associative memory. In children <5 years at CM episode but ≥5 years at cognitive testing, seizure number, background dominant frequency, and the presence of vertex sharp waves were each associated with changes in cognition; seizure number and variability with attention; and seizure number with working memory. Conclusions In children with cerebral malaria, seizure number is strongly associated with risk of long-term neurologic deficits, while seizure number and specific EEG features (average background voltage, dominant rhythm frequency, presence of vertex sharp waves, presence of variability) are independently associated with cognitive outcomes. Future studies should evaluate the predictive value of these findings.


  • Open Access

    A Case of ALG6-CDG with Explosive Onset of Intractable Epilepsy During Infancy

    by Daniel James Clark, Thomas Murray, Michael Drees, Neil Kulkarni

    ALG6-CDG is a rare, but second most common, type 1 congenital disorder of glycosylation (CDG) caused by a defect in the α-1-3-glucosyltransferase (ALG6) enzyme in the N-glycan assembly pathway. Many mutations have been identified and inherited in an autosomal recessive pattern. There are less than 100 ALG6-CDG cases reported, all sharing the phenotype of hypotonia and developmental delay. The majority (perhaps >70%) have seizures, but a minority have intractable epilepsy or epileptic encephalopathy. We report the clinical course, EEG findings, and neuroimaging of a child found to have compound heterozygous alleles c.257 + 5G > A and c.680G > A (p.G227E) who developed explosive onset of intractable epilepsy and epileptic encephalopathy. Initially, CDG was not suspected due to its rarity and lack of multi-organ system involvement, but rapid whole exam sequence (8-day turnaround) revealed the specific diagnosis quickly.


  • Prioritizing Hormone Therapy Over Vigabatrin as the First Treatment for Infantile Spasms

    by John R. Mytinger, William Parker, Steven W. Rust, Stephanie M. Ahrens, Dara V.F. Albert, Christopher W. Beatty, Julie Chrisman, Daniel J. Clark, Andrea Debs, Danielle Denney, et al.

    Background and Objectives: Infantile spasms (IS) are early childhood seizures with potentially devastating consequences. Standard therapies (adrenocorticotropic hormone [ACTH], high-dose prednisolone, and vigabatrin) are strongly recommended as the first treatment for IS. While this recommendation comes without preference for one standard therapy over another, early remission rates are higher with hormone therapy (ACTH and high-dose prednisolone) when compared to vigabatrin. Using quality improvement (QI) methodology that included hormone therapy as the first treatment, we sought to increase the percentage of children with new onset non-tuberous sclerosis complex (TSC)-associated IS achieving 3-month electroclinical remission from a mean of 53.8% to >70%. Methods: Observational cohort study using a consecutive sample at a single academic tertiary care hospital comparing a prospective intervention cohort (5/2019 – 1/2022, N = 57) to a retrospective baseline cohort (11/2015 – 4/2019, N = 67). Our initiative addressed key drivers such as the routine use of vigabatrin over hormone therapy as first treatment and the common initiation of a second treatment after 14 days for initial non-responders. We included consecutive children without TSC presenting with new onset IS diagnosed and treated between 2 – 24 months of age. We displayed our primary outcome and process measures as control charts in which the centerline is the quarterly (previous three months) mean based on statistical process control methodology. Results: QI interventions that included the standardization of hormone therapy as the first treatment resulted in higher rates of 3-month remission, rising from 53.8% (baseline cohort) to 75.9% (intervention cohort). Process measure results included an increased rate of children receiving hormone therapy as first treatment (mean 44.6% to 100%) as well as a decreased number of days to both clinical follow-up after first treatment (mean of 16.3 to 12.6 days) and starting a second treatment within 14 days for initial non-responders (mean of 36.3 to 17.2 days). Discussion: For children with IS, improved rates of 3-month electroclinical remission can be achieved with QI methodology. Implementation of similar QI initiatives at other centers may likewise improve local remission rates.


  • Housing Waste

    by Graham Cassano, Jon Carroll, Daniel J. Clark

    "Chapter 5 Housing Waste" published on 29 Jul 2021 by Brill.

  • Agonist and antagonist activity of low efficacy D2 dopamine receptor agonists in rats discriminating d-amphetamine from saline

    by M. Exner, D. Clark

    The ability of the low efficacy D2 agonists preclamol and SDZ 208–911 to both antagonise, and substitute for, the d-amphetamine discriminative cue was investigated in rats trained to discriminate d-amphetamine (0.5 mg/kg) from saline. All doses of preclamol (2.0–16.0 mg/kg) and SDZ 208–911 (0.125–1.0 mg/kg) only partially antagonised d-amphetamine discrimination. In contrast, the lower efficacy D2 agonist SDZ 208–912 completely blocked the cueing properties of d-amphetamine. Preclamol (4.0 and 16.0 mg/kg) and SDZ 208–911 (1.0 mg/kg) also partially substituted for d-amphetamine. In an additional study, the former drug enhanced the discriminative effects of a low dose of d-amphetamine (0.125 mg/kg), whilst antagonising the effects of the training dose. Preclamol also partially antagonised the ability of the selective D2 agonist quinpirole (0.125 mg/kg) to substitute for d-amphetamine. In contrast to the drug discrimination Findings, preclamol completely antagonised the loco-motor hyperactivity induced by acute d-amphetamine, in animals which had received the same long-term d-amphetamine treatment as the drug discrimination rats. The present findings reveal that preclamol and SDZ 208–911 can exert both agonist and antagonist activity in animals trained to discriminate d-amphetamine from saline. This partial agonist profile is probably due to the low efficacy D2 agonists interacting with a postsynaptic D2 receptor population possessing a higher response capability than those D2 receptors mediating d-amphetamine-induced locomotor hyperactivity.